References
- Mittal S, El-Serag HB. Epidemiology of hepatocellular carcinoma: consider the population. J Clin Gastroenterol 2013;47 Suppl:S2-6. https://doi.org/10.1097/MCG.0b013e3182872f29
- Raza A, Sood GK. Hepatocellular carcinoma review: current treatment, and evidence-based medicine. World J Gastroenterol 2014;20:4115-27. https://doi.org/10.3748/wjg.v20.i15.4115
- Ohri N, Dawson LA, Krishnan S, et al. Radiotherapy for hepatocellular carcinoma: new indications and directions for future study. J Natl Cancer Inst 2016;108;djw133. https://doi.org/10.1093/jnci/djw133
- McGlynn KA, London WT. The global epidemiology of hepatocellular carcinoma: present and future. Clin Liver Dis 2011;15:223-43, vii-x.
- Brade AM, Ng S, Brierley J, et al. Phase 1 Trial of sorafenib and stereotactic body radiation therapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2016;94:580-7. https://doi.org/10.1016/j.ijrobp.2015.11.048
- Chen SW, Lin LC, Kuo YC, Liang JA, Kuo CC, Chiou JF. Phase 2 study of combined sorafenib and radiation therapy in patients with advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2014;88:1041-7. https://doi.org/10.1016/j.ijrobp.2014.01.017
Cited by
- Overexpression of YTHDF1 is associated with poor prognosis in patients with hepatocellular carcinoma vol.21, pp.4, 2018, https://doi.org/10.3233/cbm-170791
- Systematic Analyses of the Role of the Reader Protein of N 6 -Methyladenosine RNA Methylation, YTH Domain Family 2, in Liver Hepatocellular Carcinoma vol.7, pp.None, 2017, https://doi.org/10.3389/fmolb.2020.577460
- Multiple m 6 A RNA methylation modulators promote the malignant progression of hepatocellular carcinoma and affect its clinical prognosis vol.20, pp.None, 2017, https://doi.org/10.1186/s12885-020-6638-5